WO2007070082A1 - Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone - Google Patents

Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone Download PDF

Info

Publication number
WO2007070082A1
WO2007070082A1 PCT/US2006/018000 US2006018000W WO2007070082A1 WO 2007070082 A1 WO2007070082 A1 WO 2007070082A1 US 2006018000 W US2006018000 W US 2006018000W WO 2007070082 A1 WO2007070082 A1 WO 2007070082A1
Authority
WO
WIPO (PCT)
Prior art keywords
teprenone
less
composition
nanoparticulate
release
Prior art date
Application number
PCT/US2006/018000
Other languages
English (en)
Inventor
John Devane
Paul Stark
Niall Fanning
Gurvinder Rekhi
Scott Jenkins
Gary Liversidge
Original Assignee
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma International Limited filed Critical Elan Pharma International Limited
Publication of WO2007070082A1 publication Critical patent/WO2007070082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to compositions and methods for the prevention and treatment of gastric disease.
  • the present invention relates to compositions comprising teprenone-containing particles and methods for making and using such a composition.
  • teprenone is in nanoparticulate form.
  • the present invention relates also to novel dosage forms for the controlled delivery of teprenone.
  • Teprenone is an effective therapeutic against gastric disease.
  • a healthy stomach and proper digestive processes require a fine balance of stomach acid and stomach mucosa.
  • aging, body condition, and eating habits can disrupt this delicate balance resulting in a reduction in the amount of stomach mucous, and reduced gastric peristalsis.
  • digestion time can increase, leading to conditions such as stomach heaviness and heartburn.
  • gastric mucosal lesions as a result of erosion, hemorrhage, redness and edema can lead to gastritis and gastric ulcers.
  • Teprenone increases gastric mucous, and also protects gastric mucosa from stomach acid, thereby helping to restore normal gastric mucosa and treat gastric diseases.
  • Gastritis is not necessarily clear in the special definition thereof in view of the fact that it is usually divided into acute gastritis and chronic gastritis in the discussion thereof.
  • the term is used as including both types of gastritis.
  • Chronic gastritis is usually classified into superficial gastritis and atrophic gastritis, and further into atrophic hyperplastic gastritis, hypertrophic gastritis, etc.
  • Representative examples of chronic gastritis symptoms include anorexia, esophagostenosis, pyrosis, nausea, emesis, epigastrium dysphoria, epigastralgia, and flatulence.
  • Acute gastritis is generally an inflammatory lesion of tunica mucosa ventriculi which is rapidly caused by an endogenous or xenogenic stimulus, and is usually accompanied by erosion.
  • Clinical studies have demonstrated that teprenone has a potent anti-ulcer effect and is very effective against various gastric mucosal lesions. Specifically, teprenone is thought to increase gastric mucus by promoting mucus synthesis and secretion in mucosal epithelial cells. Teprenone also increases gastric mucosal blood flow and has been shown to protect the gastric mucosa from, for example, ethanol-induced injury and increases in lipid peroxide levels. Further, teprenone enhances gastric mucosal cell proliferation and thus helps to maintain the homeostasis of the gastric mucosal cell proliferation zone.
  • Teprenone may be administered as part of a dosage form offered under the registered trademark SELBEX® by Eisai Co., Ltd. of Japan. Its chemical name is 3:2 (5E:5Z) geometric mixture of (9E,13E)-6,10,14,18-tetramethyl-5,9,13,17- nonadecatetraen-2-one.
  • the molecular formula of teprenone is C 23 H 38 O and it has a molecular weight of 330.55.
  • the chemical structure of teprenone is:
  • Teprenone occurs as a colorless to pale yellow, oily liquid. It has a slight characteristic odor, and is tasteless. It is miscible with methanol, ethanol (95), acetone, chloroform, and hexane, and is practically insoluble in water. Conventional teprenone is administered orally, either as a capsule or in fine granules, in 50 mg quantities three times daily after a meal.
  • Teprenone is described in, for example, U.S. Pat. No. 4,814,353 for "Therapeutic and Prophylactic Agent for Gastritis".
  • U.S. Pat. No. 4,814,353 describes the teprenone compound and a method for treating gastritis comprising administering a therapeutic amount of teprenone to a patient suffering from gastritis.
  • Teprenone has high therapeutic value for the treatment of patients suffering from gastritis and gastric ulcers.
  • strict patient compliance is a critical factor in the efficacy of teprenone in the treatment of gastritis and gastric ulcers.
  • Nanoparticulate active agent compositions are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto or associated with the surface thereof a non- crosslinked surface stabilizer.
  • the '684 patent does not describe nanoparticulate compositions of teprenone.
  • Nanoparticulate active agent compositions are also described, for example, in U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” 5,336,507 for “Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;” 5,340,564 for “Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;” 5,346,702 for "Use of Non-Ionic Cloud
  • the present invention then, relates to a nanoparticulate teprenone composition for the treatment of gastritis and gastric ulcers.
  • the nanoparticulate teprenone compositions of the invention have enhanced bioavailability, allowing a smaller dose to give the same in vivo blood levels.
  • the compositions of the invention also have enhanced bioavailability in the fasting state that would match that seen in the fed state and thereby eliminate the requirement to take teprenone with food.
  • the present invention relates to controlled release compositions of teprenone which eliminate the need for frequent administration.
  • the objective of many controlled release drug formulations is to produce a substantially constant release of the drug compound. Indeed, it is often a specific object of these formulations to minimize the variation in plasma concentration levels associated with conventional frequent dosage regimes. Another objective of controlled release drug formulations is to hasten the onset of action by minimizing to time from the administration of the drug to the achievement of a therapeutically effective plasma concentration. A further objective of controlled release drug formulations is to maintain a therapeutically effective plasma concentration throughout the dosing interval. The achievement of two or all three of these objectives in conventional drag formulations, however, is problematic.
  • controlled release compositions or formulations which combine the benefits of at least two different release profiles to achieve a resultant plasma profile that minimizes variations in plasma concentration levels and/or provides rapid onset of action and/or maintains a therapeutically effective plasma concentration throughout the dosing interval is desirable.
  • modified release compositions or formulations which substantially mimic the release of frequent IR dosage regimes while reducing the need for frequent dosing is desirable.
  • a typical example of a drag which may produce tolerance in patients is rnethylphenidate.
  • Methylphenidate, or ⁇ -phenyl-2-piperidine acetic acid methyl ester is a stimulant affecting the central nervous and respiratory systems and is primarily used in the treatment of attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • GIT gastrointestinal tract
  • drag effects persist for 3-6 hours after oral administration of conventional IR tablets or up to about 8 hours after oral administration of extended release formulations.
  • the total dosage is typically in the range of 5-30 mg per day, in exceptional cases rising to 60 mg/day.
  • methylphenidate is given twice daily, typically with one dose given before breakfast and a second dose given before lunch.
  • the last daily dose is preferably given several hours before retiring.
  • Adverse effects associated with methylphenidate treatment include insomnia and the development of patient tolerance.
  • WO 98/14168 (Alza Corp.) teaches a dosage form and a method of administering methylphenidate in a sustained and constantly ascending rate.
  • the dosage form disclosed comprises a plurality of beads comprising a hydrogel matrix with increasing amounts of the active ingredient therein, coated with varying amounts of a release rate controlling material. Appropriate combinations of the active ingredient dose and the number and thickness coating layers can be selected to give an ascending release profile in which the plasma concentration of the active ingredient continually increases over a given period of time.
  • An object of WO 98/14168 is to release a dosage form at a constantly ascending rate specifically to avoid uneven blood levels (characterized by peaks and troughs) associated with conventional treatments using immediate release dosage formulations. As a result, this formulation does not deliver the active ingredient in either a pulsatile or a bimodal manner.
  • WO 97/03672 discloses that methylphenidate exhibits a therapeutic effect when administered in the form of a racemic mixture or in the form of a single isomer (such as the RR d-threo enantiomer). Further, WO 97/03763 (Chiroscience Ltd.) discloses a sustained release formulation containing d-threo methylphenidate
  • composition comprising a coating through which the dtmp passes in order to attain sustained release and achieve serum levels (of the active ingredient) of at least 50% cmax over a period of at least 8 hours.
  • serum levels of the active ingredient
  • Giunchedi et al. Int. J. Pharm (1991) 77:177-181 discloses the use of a hydrophilic matrix multiple-unit formulation for the pulsed release of ketoprofen.
  • Giunchedi et al. teach that ketoprofen is rapidly eliminated from the blood after dosing (plasma half-life 1-3 hours) and consecutive pulses of drug may be more beneficial than constant release for some treatments.
  • the multiple-unit formulation disclosed comprises four identical hydrophilic matrix tablets placed in a gelatin capsule. Although the in vivo studies show two peaks in the plasma profile there is no well defined wash out period and the variation between the peak and trough plasma levels is small.
  • the three layer tablet is made up of a first layer containing the active ingredient, a barrier layer (the second layer) of semi-permeable material which is interposed between the first layer and a third layer containing an additional amount of active ingredient.
  • the barrier layer and the third layer are housed in an impermeable casing.
  • the first layer dissolves upon contact with a dissolving fluid while the third layer is only available after dissolution or rupture of the barrier layer. In such a tablet the first portion of active ingredient must be released instantly.
  • This approach also requires the provision of a semi-permeable layer between the first and third layers in order to control the relative rates of delivery of the two portions of active ingredient. Additionally, rupture of the semi-permeable layer leads to uncontrolled dumping of the second portion of the active ingredient which may not be desirable.
  • U.S. Pat. No. 5,158,777 discloses a formulation comprising captopril within an enteric or delayed release coated pH stable core combined with additional captopril which is available for immediate release following administration.
  • chelating agents such as disodium edetate or surfactants such as polysorbate 80 are used either alone or in combination with a buffering agent.
  • the compositions have an amount of captopril available for immediate release following oral administration and an additional amount of pH stabilized captopril available for release in the colon.
  • U.S. Pat. Nos. 4,728,512, 4,794,001 and 4,904,476 relate to preparations providing three distinct releases.
  • the preparation contains three groups of spheroids containing an active medicinal substance: the first group of spheroids is uncoated and rapidly disintegrates upon ingestion to release an initial dose of medicinal substance; the second group of spheroids is coated with a pH sensitive coat to provide a second dose; and the third group of spheroids is coated with a pH independent coat to provide to third dose.
  • the preparation is designed to provide repeated release of medicinal substances which are extensively metabolized presystemically or have relatively short elimination half-lives.
  • U.S. Pat. No. 5,837,284 discloses a methylphenidate dosage form having immediate release and delayed release particles.
  • the delayed release is provided by the use of ammonio methacrylate pH independent polymers combined with certain fillers.
  • the present invention relates to nanoparticulate compositions comprising teprenone.
  • the compositions comprise nanoparticulate teprenone particles, and at least one surface stabilizer adsorbed on or associated with the surface of the teprenone particles.
  • the nanoparticulate teprenone particles have an effective average particle size of less than about 2,000 nm.
  • the present invention provides nanoparticulate teprenone compositions which overcome the poor bioavailability of conventional, non-nanoparticulte teprenone and eliminate the requirement to take the product with food.
  • the present invention also provides controlled release compositions of teprenone which eliminate the need to take teprenone three times a day.
  • a preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
  • Another aspect of the invention is directed to pharmaceutical compositions comprising a nanoparticulate teprenone particle and at least one surface stabilizer, a pharmaceutically acceptable carrier, as well as any desired excipients.
  • One embodiment of the invention encompasses a nanoparticulate teprenone composition, wherein the pharmacokinetic profile of the nanoparticulate teprenone is not affected by the fed or fasted state of a subject ingesting the composition.
  • the invention encompasses a nanoparticulate teprenone composition, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
  • Another embodiment of the invention is directed to nanoparticulate teprenone compositions comprising one or more additional compounds useful in the prevention and treatment of gastritis and gastric ulcers.
  • This invention further discloses a method of making the inventive nanoparticulate teprenone composition.
  • Such a method comprises contacting the nanoparticulate teprenone with at least one surface stabilizer for a time and under conditions sufficient to provide a stabilized nanoparticulate teprenone composition.
  • the present invention is also directed to methods of treatment including but not limited to, the prevention and treatment of gastritis and gastric ulcers using the novel nanoparticulate teprenone compositions disclosed herein.
  • Such methods comprise administering to a subject a therapeutically effective amount of a nanoparticulate teprenone composition.
  • Other methods of treatment using the nanoparticulate compositions of the invention are known to those of skill in the art.
  • the present invention further relates to a controlled release composition
  • a controlled release composition comprising a teprenone or a nanoparticulate teprenone which, in operation, produces a plasma profile substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially.
  • the present invention relates to a controlled release composition that, in operation, delivers a teprenone or a nanoparticulate teprenone, in a pulsatile or continuous manner, preferably during a period of up to twenty-four hours.
  • Another object of the invention which substantially mimics the pharmac administration of three or more IR dosage torms comprising a teprenone or a nanoparticulate teprenone given sequentially.
  • Another object of the invention is to provide a controlled release composition which substantially reduces or eliminates the development of patient tolerance to a teprenone or a nanoparticulate teprenone.
  • Another object of the invention is to provide a controlled release composition in which a first portion of the composition, i.e., a teprenone or a nanoparticulate teprenone, is released immediately upon administration and a second portion of the active ingredient is released rapidly after an initial delay period and a third portion of the active ingredient is released rapidly after an initial delay period in a multi-modal manner.
  • a first portion of the composition i.e., a teprenone or a nanoparticulate teprenone
  • Another object of the invention is to formulate the dosage in the form of erodable formulations, diffusion controlled formulations, or osmotic controlled formulations.
  • Another object of the invention is to provide a controlled release composition capable of releasing a teprenone or a nanoparticulate teprenone, in a bimodal or multimodal manner in which a first portion of the active is released either immediately or after a delay time to provide a pulse of drug release and one or more additional portions of the teprenone or a nanoparticulate teprenone is released, after a respective lag time, to provide additional pulses of drug release during a period of up to twenty-four hours.
  • Another object of the invention is to provide solid oral dosage forms comprising a controlled release composition comprising a teprenone or a nanoparticulate teprenone. Yet another object of the inventi pain and/or inflammation comprising th invention.
  • Nanoparticulate Teprenone Compositions comprising a teprenone.
  • the compositions comprise a teprenone and preferably at least one surface stabilizer adsorbed on the surface of the drug.
  • the teprenone particles have an effective average particle size of less than about 2000 nm.
  • nanoparticulate teprenone formulation of the invention include, but are not limited to: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect as compared to conventional microcrystalline forms of a teprenone; (3) increased bioavailability as compared to conventional microcrystalline forms of teprenone; (4) substantially similar pharmacokinetic profiles of the teprenone compositions when administered in the fed versus the fasted state; (5) bioequivalency of the teprenone compositions when administered in the fed versus the fasted state; (6) an increased rate of dissolution for the teprenone compositions as compared to conventional microcrystalline forms of the same teprenone; (7) the teprenone compositions can be used in conjunction with other active agents useful in the prevention and treatment of gastritis and gastric ulcers.
  • the present invention also includes nanoparticulate teprenone compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
  • the compositions can be formulated for parental injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments, or drops), buccal, intracisternal, intraperitoneal, or topical administrations, and the like.
  • a preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
  • Exemplary solid dosage forms include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
  • a solid dose tablet formulation is preferred.
  • effective average particle size of less than about 2000 nm means that at least 50% of the teprenone particles have a size, by weight or other suitable measurement (i.e., volume, number, etc.), of less than about 2000 nm, when measured by, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, disk centrifugation, and other techniques known to those of skill in the art.
  • non-nanoparticulate teprenone means teprenone which is solubilized or which has an effective average particle size of greater than about 2000 nm.
  • Nanoparticulate active agents as defined herein have an effective average particle size of less than about 2000 nm.
  • the phrase "therapeutically effective amount” shall mean the drug dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that a therapeutically effective amount of a drug that is administered to a particular subject in a particular instance will not always be effective in treating the conditions/diseases described herein, even though such dosage is deemed to be a therapeutically effective amount by those of skill in the art.
  • the term “particulate” as used herein refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology.
  • the term “multiparticulate” as used herein means a plurality of discrete, or aggregated, particles, pellets, beads, granules or mixture thereof irrespective of their size, shape or morphology.
  • nanoparticulate teprenone formulations of the invention are proposed to exhibit increased bioavailability, and require smaller doses as compared to prior conventional teprenone formulations.
  • the invention also preferably provides compositions comprising nanoparticulate teprenone and having a desirable pharmacokinetic profile when administered to mammalian subjects.
  • the desirable pharmacokinetic profile of the compositions comprising teprenone preferably includes, but is not limited to: (1) a C max for teprenone, when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the C max for a non-nanoparticulate formulation of teprenone, administered at the same dosage; and/or (2) an AUC for teprenone, when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the AUC for a non-nanoparticulate formulation of teprenone, administered at the same dosage; and/or (3) a T max for teprenone, when assayed in the plasma of a mammalian subject following administration, that is preferably less than the T max for a non
  • the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of teprenone.
  • a composition comprising nanoparticulate teprenone exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of teprenone, administered at the same dosage, a T max not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the T max exhibited by the non-nanoparticulate teprenone formulation.
  • the composition comprising nanoparticulate teprenone exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of teprenone, administered at the same dosage, a C ma .
  • N which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the C max exhibited by the non- nanoparticulate teprenone formulation.
  • the composition comprising nanoparticulate teprenone exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of teprenone, administered at the same dosage, an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nanoparticul
  • the invention encompasses teprenone composition wherein the pharmacokinetic profile of teprenone is not substantially affected by the fed or fasted state of a subject ingesting the composition. This means that there is no substantial difference in the quantity of drug absorbed or the rate of drug absorption when the nanoparticulate teprenone compositions are administered in the fed versus the fasted state.
  • teprenone formulations i.e., SELBEX®
  • the absorption of teprenone is increased when administered with food. This difference in absorption observed with conventional teprenone formulations is undesirable.
  • the teprenone formulations of the invention overcome this problem, as the teprenone formulations reduce or preferably substantially eliminate significantly different absorption levels when administered under fed as compared to fasting conditions.
  • Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant, as with poor subject compliance an increase in the medical condition for which the drug is being prescribed may be observed, i.e., NSCLC for poor subject compliance with teprenone.
  • the invention also encompasses provides a nanoparticulate teprenone composition in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
  • the difference in absorption of the teprenone compositions of the invention, when administered in the fed versus the fasted state preferably is less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
  • the invention encompasses compositions comprising nanoparticulate teprenone, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, in particular as defined by C max and AUC guidelines given by the U.S. Food and Drug Administration and the corresponding European regulatory agency (EMEA).
  • EMEA European regulatory agency
  • two products or methods are bioequivalent if the 90% Confidence Intervals (CI) for AUC and C m3x are between 0.80 to 1.25 (T max measurements are not relevant to bioequivalence for regulatory purposes).
  • the 90% CI for AUC must be between 0.80 to 1.25 and the 90% CI for C m a x must between 0.70 to 1.43.
  • the nanoparticulate teprenone compositions of the invention are proposed to have unexpectedly dramatic dissolution profiles. Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to faster onset of action and greater bioavailability. To improve the dissolution profile and bioavailability of the teprenone, it would be useful to increase the drug's dissolution so that it could attain a level close to 100%.
  • the teprenone compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the composition is dissolved. In other embodiments of the invention, at least about 30% or at least about 40% of teprenone composition is dissolved within about 5 minutes.
  • preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the teprenone composition is dissolved within about 10 minutes.
  • preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the teprenone composition is dissolved within about 20 minutes.
  • Dissolution is preferably measured in a medium which is discriminating. Such a dissolution medium will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of in vivo dissolution of a composition.
  • An exemplary dissolution medium is an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution. 6. Redispersibility Profiles of the Teprenone Compositions of the Invention
  • compositions of the invention redisperse such that the effective average particle size of the redispersed teprenone particles is less than about 2 microns. This is significant, as if upon administration the teprenone compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the dosage form may lose the benefits afforded by formulating the teprenone into a nanoparticulate particle size.
  • nanoparticulate active agent compositions benefit from the small particle size of the active agent; if the active agent does not redisperse into the small particle sizes upon administration, then "clumps" or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate active agent.
  • the nanoparticulate teprenone compositions of the invention exhibit dramatic redispersion of the nanoparticulate teprenone particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed teprenone particles is less than about 2 microns.
  • biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media.
  • the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
  • Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
  • Such redispersion in a biorelevant media is predictive of in vivo efficacy of the teprenone dosage form.
  • Biorelevant pH is well known in the art. For example, in the stomach, the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5. In the small intestine the pH can range from 4 to 6, and in the colon it can range from 6 to 8. Biorelevant ionic strength is also well known in the art.
  • Fasted state gastric fluid has an ionic strength of about 0.1 M while fasted state intestinal fluid has an ionic strength of about 0.14.
  • ionic strength of about 0.1 M
  • fasted state intestinal fluid has an ionic strength of about 0.14.
  • pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
  • electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 N, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
  • electrolyte solutions can be, but are not limited to, about 0.1 N HCl or less, about 0.01 N HCl or less, about 0.001 N HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
  • 0.01 N HCl and/or 0.1 M NaCl are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract.
  • Electrolyte concentrations of 0.001 N HCl, 0.01 N HCl, and 0.1 N HCl correspond to pH 3, pH 2, and pH 1, respectively.
  • a 0.01 N HCl solution simulates typical acidic conditions found in the stomach.
  • a solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
  • Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride.
  • the redispersed teprenone particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 2000 run, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 650 nm, less than about 600 nm, less than about 550 nm, less than about 500 nm, less than about 450 nm, less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 150
  • Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate.”
  • Teprenone Compositions used in Conjunction with Other Active Agents can additionally comprise one or more compounds useful in treating gastritis and gastric ulcers, or the teprenone compositions can be administered in conjunction with such a compound.
  • examples of such compounds include, but are not limited to, proton pump inhibitors such as omeprazole and lansoprazole, H2 receptor blockers such as cimetidine, ranitidine, famotidine, and nizatidine, agents that protect the stomach lining such as sucralfate, bismuth, misoprostol, and antacids, antibiotics, and acetominophin.
  • proton pump inhibitors such as omeprazole and lansoprazole
  • H2 receptor blockers such as cimetidine, ranitidine, famotidine, and nizatidine
  • agents that protect the stomach lining such as sucralfate, bismuth, misoprostol, and antacids, antibiotics,
  • the invention provides compositions comprising teprenone particles and at least one surface stabilizer.
  • the surface stabilizers preferably are adsorbed on, or associated with, the surface of the teprenone particles.
  • Surface stabilizers especially useful herein preferably physically adhere on, or associate with, the surface of the nanoparticulate teprenone particles, but do not chemically react with the teprenone particles or itself.
  • Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
  • the present invention also includes teprenone compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
  • the compositions can be formulated for parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
  • compositions of the invention comprise particles of teprenone, or a polymorph or variant thereof.
  • the teprenone particles can be crystalline, semi-crystalline, amorphous, semi-amorphous, or a combination thereof.
  • Combinations of more than one surface stabilizers can be used in the invention.
  • Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Exemplary surface stabilizers include nonionic, anionic, cationic, ionic, and zwitterionic surfactants or compounds.
  • surface stabilizers include hydroxypropyl methylcellulose (now known as hypromellose), hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alky] ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween 80 ® (ICI Speciality Chemicals)); polyethylene glycol glyco
  • cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
  • cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, Ci 2- ] 5 dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide,
  • alkyl pyridinium salts such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[diallyl dimethylammonium chloride] and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar.
  • amines such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine
  • amine salts such as lauryl amine acetate,
  • Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
  • Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR]R 2 R 3 R 4 ⁇ .
  • none OfR]-R 4 are CH 3 ; (iii) three of R] -R 4 are CH 3 ; (iv) all Of Ri-R 4 are CH 3 ; (v) two of R] -R 4 are CH 3 , one OfRi-R 4 is C 6 HsCH 2 , and one of Ri-R 4 is an alkyl chain of seven carbon atoms or less; (vi) two OfRi-R 4 are CH 3 , one OfRj-R 4 is C 6 H 5 CH 2 , and one Of Ri-R 4 is an alkyl chain of nineteen carbon atoms or more;
  • Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quatemium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylben ⁇ yl ammonium chloride(Quaternium- 14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, dietlianolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecyl
  • the surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference.
  • compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
  • excipients are known in the art.
  • filling agents are lactose monohydrate, lactose anhydrous, and various starches
  • binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PH 102, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM).
  • Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
  • preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
  • Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
  • examples of diluents include microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress " ; mannitol; starch; sorbitol; sucrose; and glucose.
  • Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof.
  • effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
  • Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
  • Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
  • sodium bicarbonate component of the effervescent couple may be present.
  • compositions of the invention contain nanoparticulate teprenone particles which have an effective average particle size of less than about 2000 nm (i.e., 2 microns), less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods.
  • an effective average particle size of less than about 2000 nm it is meant that at least 50% of the teprenone particles have a particle size of less than the effective average, by weight (or by another suitable method, e.g., volume, number, etc.), i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques.
  • At least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% of the teprenone particles have a particle size of less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
  • the value for D50 of a nanoparticulate teprenone composition is the particle size below which 50% of the teprenone particles fall, by weight.
  • D90 is the particle size below which 90% of the teprenone particles fall, by weight.
  • the relative amounts of teprenone and one or more surface stabilizers can vary widely.
  • the optimal amount of the individual components can depend, for example, upon the particular teprenone selected, the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
  • the concentration of the teprenone can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the teprenone and at least one surface stabilizer, not including other excipients.
  • the concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the teprenone and at least one surface stabilizer, not including other excipients.
  • exemplary teprenone tablet formulations are given below. These examples are not intended to limit the claims in any respect, but rather to provide exemplary tablet formulations of teprenone which can be utilized in the methods of the invention. Such exemplary tablets can also comprise a coating agent.
  • Nanoparticulate Teprenone compositions can be made using, for example, milling, homogenization, precipitation, freezing or supercritical fluids, or template emulsion techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making Methods of making nanoparticulate compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,862,999 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No.
  • the resultant nanoparticulate teprenone compositions or dispersions can be utilized in solid or liquid dosage formulations, such as liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, etc.
  • Milling a teprenone to obtain a nanoparticulate dispersion comprises dispersing the teprenone particles in a liquid dispersion medium in which the teprenone is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the teprenone to the desired effective average particle size.
  • the dispersion medium can be, for example, water, safflower oil, ⁇ thanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
  • a preferred dispersion medium is water.
  • the teprenone particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, teprenone particles can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the teprenone/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
  • Another method of fo ⁇ ning the desired nanoparticulate teprenone composition is by microprecipitation.
  • This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
  • Such a method comprises, for example: (1) dissolving the teprenone in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
  • the method can be followed by removal of any formed salt, if present, by dialysis or diaf ⁇ ltration and concentration of the dispersion by conventional means.
  • Such a method comprises dispersing particles of a teprenone in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of a teprenone to the desired effective average particle size.
  • the teprenone particles can be reduced in size in the presence of at least one surface stabilizer.
  • the teprenone particles can be contacted with one or more surface stabilizers either before or after attrition.
  • Other compounds, such as a diluent can be added to the teprenone/surface stabilizer composition either before, during, or after the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • Another method of forming the desired nanoparticulate teprenone composition is by spray freezing into liquid (SFL).
  • SFL liquid
  • This technology comprises an organic or organoaqueous solution of teprenone with stabilizers, which is injected into a cryogenic liquid, such as liquid nitrogen.
  • the droplets of the teprenone solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nanostructured teprenone particles.
  • the nanoparticulate teprenone particles can have varying particle morphology.
  • the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the teprenone particles.
  • ultra rapid freezing may also be used to created equivalent nanostructured teprenone particles with greatly enhanced surface area.
  • URF comprises taking a water-miscible, anhydrous, organic, or organoaqueous solution of teprenone with stabilizers and applying it onto a cryogenic substrate. The solvent is then removed by means such as lyophilization or atmospheric freeze-drying with the resulting nanostructured teprenone remaining.
  • Emulsion Methodologies to Obtain Nanoparticulate Teprenone Compositions Another method of forming the desired nanoparticulate teprenone composition is by template emulsion.
  • Template emulsion creates nanostructured teprenone particles with controlled particle size distribution and rapid dissolution performance.
  • the method comprises an oil-in-water emulsion that is prepared, then swelled with a non-aqueous solution comprising the teprenone and stabilizers.
  • the particle size distribution of the teprenone particles is a direct result of the size of the emulsion droplets prior to loading with the teprenone a property which can be controlled and optimized in this process.
  • emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the stabilized nanostructured teprenone particles are recovered. Various teprenone particles morphologies can be achieved by appropriate control of processing conditions.
  • the invention provides a method of increasing bioavailability of a teprenone in a subject. Such a method comprises orally administering to a subject an effective amount of a composition comprising a teprenone.
  • the teprenone composition in accordance with standard pharmacokinetic practice, has a bioavailability that is about 50% greater, about 40% greater, about 30% greater, about 20% greater, or about 10% greater than a conventional non-nanoparticulate teprenone dosage form.
  • compositions of the invention are useful in the prevention and treatment of gastritis and gastric ulcers.
  • the teprenone compounds of the invention can be administered to a subject via any conventional means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray.
  • parenterally e.g., intravenous, intramuscular, or subcutaneous
  • intracisternally e.g., intravenous, intramuscular, or subcutaneous
  • pulmonary e.g., intravaginally
  • intraperitoneally e.g., powders, ointments or drops
  • buccal or nasal spray e.g., a buccal or nasal spray.
  • subject is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably.
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • the nanoparticulate teprenone compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules.
  • the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
  • Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • oils such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil
  • glycerol tetrahydrofurfuryl alcohol
  • polyethyleneglycols fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • “Therapeutically effective amount” as used herein with respect to a teprenone, dosage shall mean that dosage that provides the specific pharmacological response for which a teprenone is administered in a significant number of subjects in need of such treatment. It is emphasized that 'therapeutically effective amount,' administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a 'therapeutically effective amount' by those skilled in the art. It is to be further understood that teprenone dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
  • teprenone effective amounts can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form.
  • Actual dosage levels of a teprenone in the nanoparticulate compositions of the invention may be varied to obtain an amount of a teprenone that is effective to obtain a desired therapeutic response for a particular composition and method of administration.
  • the selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered teprenone, the desired duration of treatment, and other factors.
  • Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
  • the effectiveness of pharmaceutical compounds in the prevention and treatment of disease states depends on a variety of factors including the rate and duration of delivery of the compound from the dosage form to the patient.
  • the combination of delivery rate and duration exhibited by a given dosage form in a patient can be described as its in vivo release profile and, depending on the pharmaceutical compound administered, will be associated with a concentration and duration of the pharmaceutical compound in the blood plasma, referred to as a plasma profile.
  • a plasma profile concentration and duration of the pharmaceutical compound in the blood plasma
  • the release profiles of dosage forms may exhibit different rates and durations of release and may be continuous or pulsatile.
  • Continuous release profiles include release profiles in which a quantity of one or more pharmaceutical compounds is released continuously throughout the dosing interval at either a constant or variable rate.
  • Pulsatile release profiles include release profiles in which at least two discrete quantities of one or more pharmaceutical compounds are released at different rates and/or over different time frames. For any given pharmaceutical compound or combination of such compounds, the release profile for a given dosage form gives rise to an associated plasma profile in a patient.
  • the release profile of the dosage form as a whole is a combination of the individual release profiles and may be described generally as "multimodal.”
  • the release profile of a two-component dosage form in which each component has a different release profile may described as "bimodal," and the release profile of a three-component dosage form in which each component has a different release profile may described as "trimodal.”
  • the associated plasma profile in a patient may exhibit constant or variable blood plasma concentration levels of the pharmaceutical compounds over the duration of action and may be continuous or pulsatile.
  • Continuous plasma profiles include plasma profiles of all rates and duration which exhibit a single plasma concentration maximum.
  • Pulsatile plasma profiles include plasma profiles in which at least two higher blood plasma concentration levels of pharmaceutical compound are separated by a lower blood plasma concentration level and may be described generally as “multimodal.” Pulsatile plasma profiles exhibiting two peaks may be described as “bimodal” and plasma profiles exhibiting three peaks may be described as “trimodal.” Depending on, at least in part, the pharmacokinetics of the pharmaceutical compounds included in the dosage form as well as the release profiles of the individual components of the dosage form, a multimodal release profile may result in either a continuous or a pulsatile plasma profile upon administration to a patient.
  • the present invention provides a multiparticulate modified release composition which delivers teprenone in a pulsatile manner.
  • the present invention provides a multiparticulate modified release composition which delivers teprenone in a continuous manner.
  • the present invention provides a multiparticulate modified release composition in which a first portion of teprenone is released immediately upon administration and one or more subsequent portions of teprenone are released after an initial time delay.
  • the present invention provides solid oral dosage forms for once-daily or twice-daily administration comprising the multiparticulate modified release composition of the present invention.
  • the present invention provides a multiparticualte modified release composition in which the particles comprise teprenone-containing nanoparticles of the type described above.
  • the present invention provides a method for the prevention and/or treatment of gastric disease comprising the administration of a composition of the present invention.
  • a pharmaceutical composition having a first component comprising active ingredient- containing particles, and at least one subsequent component comprising active ingredient- containing particles, each subsequent component having a rate and/or duration of release different from the first component wherein at least one of said components comprises teprenone-containing particles.
  • the teprenone-containing particles may be coated with a modified release coating. Alternatively or additionally, the teprenone-containing particles may comprise a modified release matrix material. Following oral delivery, the composition delivers teprenone in a pulsatile manner.
  • the first component provides an immediate release of teprenone and the one or more subsequent components provide a modified release of teprenone.
  • the immediate release component serves to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and the one or more subsequent components serve to minimize the variation in plasma concentration levels and/or maintain a therapeutically effective plasma concentration throughout the dosing interval.
  • the modified release coating and/or the modified release matrix material cause a lag time between the release of the active ingredient from the first population of active ingredient-containing particles and the release of the active ingredient from subsequent populations of active ingredient-containing particles.
  • the modified release coating and/or the modified release matrix material causes a lag time between the release of the active ingredient from the different populations of active ingredient-containing particles.
  • the duration of these lag times may be varied by altering the composition and/or the amount of the modified release coating and/or altering the composition and/or amount of modified release matrix material utilized.
  • the duration of the lag time can be designed to mimic a desired plasma profile.
  • the modified release composition of the present invention is particularly useful for administering a teprenone which is normally administered three times daily.
  • the composition delivers the teprenone in a trimodal manner. Upon administration, such a composition produces a plasma profile which substantially mimics that obtained by the sequential administration of three IR doses of teprenone in accordance with a typical treatment regimen.
  • the composition can be designed to produce a plasma profile that minimizes or eliminates the variations in plasma concentration levels associated with the administration of two or more IR dosage forms given sequentially.
  • the composition may be provided with an immediate release component to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and at least one modified release component to maintain a therapeutically effective plasma concentration level throughout the dosing interval.
  • pill refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology.
  • multiparticulate as used herein means a plurality of discrete or aggregated particles, pellets, beads, granules, or mixtures thereof, irrespective of their size, shape or morphology.
  • modified release as used herein includes a release which is not immediate and includes controlled release, extended release, sustained release and delayed release.
  • time delay refers to the period of time between the administration of a dosage form comprising the composition of the invention and the release of the active ingredient from a particular component thereof.
  • lag time refers to the time between the release of the active ingredient from one component of the composition and the release of the active ingredient from another component of the composition.
  • electrode refers to formulations which may be worn away, diminished, or deteriorated by the action of substances within the body.
  • diffusion controlled refers to formulations which may spread as the result of their spontaneous movement, for example, from a region of higher to one of lower concentration.
  • osmotic controlled refers to formulations which may spread as the result of their movement through a semi-permeable membrane into a solution of higher concentration that tends to equalize the concentrations of the formulation on the two sides of the membrane.
  • the active ingredients in each component may be the same or different.
  • the composition may comprise components comprising only teprenone as the active ingredient.
  • the composition may comprise a first component comprising teprenone and at least one subsequent component comprising an active ingredient other than teprenone suitable for coadministration with teprenone, or a first component containing an active ingredient other than teprenone and at least one subsequent component comprising teprenone.
  • two or more active ingredients may be incorporated into the same component when the active ingredients are compatible with each other.
  • an active ingredient present in one component of the composition may be accompanied by, for example, an enhancer compound or a sensitizer compound in another component of the composition, in order to modify the bioavailability or therapeutic effect thereof.
  • an enhancer compound or a sensitizer compound in another component of the composition, in order to modify the bioavailability or therapeutic effect thereof.
  • the term “enhancer” refers to a compound which is capable of enhancing the absorption and/or bioavailability of an active ingredient by promoting net transport across the GIT in an animal, such as a human.
  • Enhancers include but are not limited to medium chain fatty acids; salts, esters, ethers and derivatives thereof, including glycerides and triglycerides; non-ionic surfactants such as those that can be prepared by reacting ethylene oxide with a fatty acid, a fatty alcohol, an alkylphenol or a sorbitan or glycerol fatty acid ester; cytochrome P450 inhibitors, P-glycoprotein inhibitors and the like; and mixtures of two or more of these agents.
  • the proportion of teprenone contained in each component may be the same or different depending on the desired dosing regime.
  • the teprenone present in the first component and in subsequent components may be any amount sufficient to produce a therapeutically effective plasma concentration level.
  • the teprenone, when applicable, may be present either in the form of one substantially optically pure stereoisomer or as a mixture, racemic or otherwise, of two or more stereoisomers.
  • the teprenone is preferably present in the composition in an amount of from about 0.1 to about 500 mg, preferably in the amount of from about 1 to about 100 mg.
  • the teprenone is preferably present in the first component in an amount of from about 0.5 to about 60 mg; more preferably the teprenone, is present in the first component in an amount of from about 2.5 to about 30 mg.
  • the teprenone is present in subsequent components in an amount within similar ranges to those described for the first component.
  • the time release characteristics for the delivery of the teprenone from each of the components may be varied by modifying the composition of each component, including modifying any of the excipients and/or coatings which may be present.
  • the release of the teprenone may be controlled by changing the composition and/or the amount of the modified release coating on the particles, if such a coating is present. If more than one modified release component is present, the modified release coating for each of these components may be the same or different.
  • release of the active ingredient may be controlled by the choice and amount of modified release matrix material utilized.
  • the modified release coating may be present, in each component, in any amount that is sufficient to yield the desired delay time for each particular component.
  • the modified release coating may be preset, in each component, in any amount that is sufficient to yield the desired time lag between components.
  • the lag time and/or time delay for the release of the teprenone from each component may also be varied by modifying the composition of each of the components, including modifying any excipients and coatings which may be present.
  • the first component may be an immediate release component wherein the teprenone is released immediately upon administration.
  • the first component may be, for example, a time-delayed immediate release component in which the teprenone is released substantially in its entirety immediately after a time delay.
  • the second and subsequent component may be, for example, a time-delayed immediate release component as just described or, alternatively, a time-delayed sustained release or extended release component in which the teprenone is released in a controlled fashion over an extended period of time.
  • the exact nature of the plasma concentration curve will be influenced by the combination of all of these factors just described.
  • the lag time between the delivery (and thus also the onset of action) of the teprenone in each component may be controlled by varying the composition and coating (if present) of each of the components.
  • numerous release and plasma profiles may be obtained.
  • the duration of the lag time between the release of the teprenone from each component and the nature of the release of the teprenone from each component i.e.
  • the plasma profile may be continuous (i.e., having a single maximum) or pulsatile in which the peaks in the plasma profile may be well separated and clearly defined (e.g. when the lag time is long) or superimposed to a degree (e.g. when the lag time is short).
  • the plasma profile produced from the administration of a single dosage unit comprising the composition of the present invention is advantageous when it is desirable to deliver two or more pulses of active ingredient without the need for administration of two or more dosage units. Additionally, in the case of treating pain and/or inflammation, it is particularly useful to have such a multimodal plasma profile.
  • a typical teprenone treatment regime consists of the administration of two or three doses of an immediate release dosage formulation given four hours apart. This type of regime has been found to be therapeutically effective and is widely used.
  • coating materials suitable for use in the practice of the present invention include but are not limited to polymer coating materials, such as cellulose acetate phthalate, cellulose acetate trimaletate, hydroxy propyl methylcellulose phthalate, polyvinyl acetate phthalate, ammonio methacrylate copolymers such as those sold under the trademark Eudragit RS and RL, poly acrylic acid and poly acrylate and methacrylate copolymers such as those sold under the trademark Eudragit ® S and L, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, shellac; hydrogels and gel-forming materials, such as carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl alcohol, hydroxyethyl cellulose, methyl cellulose, gelatin, starch
  • polyvinylpyrrolidone mol. wt. ⁇ 10k-360k
  • anionic and cationic hydrogels polyvinyl alcohol having a low acetate residual, a swellable mixture of agar and carboxymethyl cellulose, copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene, pectin (mol. wt. ⁇ 30k-300k), polysaccharides such as agar, acacia, karaya, tragacanth, algins and guar, polyacrylamides, Polyox ® polyethylene oxides (mol. wt.
  • AquaKeep ® acrylate polymers diesters of polyglucan, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone, sodium starch glucolate (e.g. Explotab ; Edward Mandell C. Ltd.); hydrophilic polymers such as polysaccharides, methyl cellulose, sodium or calcium carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, nitro cellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g.
  • Polyox ® Union Carbide
  • Eudragit ® Rohm and Haas
  • other acrylic acid derivatives other acrylic acid derivatives
  • sorbitan esters natural gums, lecithins, pectin, alginates, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, agar, and gums such as arabic, karaya, locust bean, tragacanth, carrageens, guar, xanthan, scleroglucan and mixtures and blends thereof.
  • excipients such as plasticisers, lubricants, solvents and the like may be added to the coating.
  • Suitable plasticisers include for example acetylated monoglycerides; butyl phthalyl butyl glycolate; dibutyl tartrate; diethyl phthalate; dimethyl phthalate; ethyl phthalyl ethyl glycolate; glycerin; propylene glycol; triacetin; citrate; tripropioin; diacetin; dibutyl phthalate; acetyl monoglyceride; polyethylene glycols; castor oil; triethyl citrate; polyhydric alcohols, glycerol, acetate esters, gylcerol triacetate, acetyl triethyl citrate, dibenzyl phthalate, dihexyl phthalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, epoxidised tallate, triis
  • modified release component comprises a modified release matrix material
  • any suitable modified release matrix material or suitable combination of modified release matrix materials may be used. Such materials are known to those skilled in the art.
  • modified release matrix material includes hydrophilic polymers, hydrophobic polymers and mixtures thereof which are capable of modifying the release of a teprenone dispersed therein in vitro or in vivo.
  • Modified release matrix materials suitable for the practice of the present invention include but are not limited to microcrystalline cellulose, sodium carboxymethylcellulose, hydoxyalkylcelluloses such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyethylene oxide, alkylcelluloses such as methylcellulose and ethylcellulose, polyethylene glycol, polyvinylpyrrolidone, cellulose acteate, cellulose acetate butyrate, cellulose acteate phthalate, cellulose acteate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixture thereof.
  • a modified release composition according to the present invention may be incorporated into any suitable dosage form which facilitates release of the active ingredient in a pulsatile manner.
  • the dosage form comprises a blend of different populations of active ingredient-containing particles which make up the immediate release and the modified release components, the blend being filled into suitable capsules, such as hard or soft gelatin capsules.
  • the different individual populations of active ingredient-containing particles may be compressed (optionally with additional excipients) into mini-tablets which may be subsequently filled into capsules in the appropriate proportions.
  • Another suitable dosage form is that of a multilayer tablet. In this instance the first component of the modified release composition may be compressed into one layer, with the second component being subsequently added as a second layer of the multilayer tablet.
  • the populations of teprenone-containing particles making up the composition of the invention may further be included in rapidly dissolving dosage forms such as an effervescent dosage form or a fast-melt dosage form.
  • the composition comprises at least two teprenone components: a first teprenone component and one or more subsequent teprenone components.
  • the first teprenone component of the composition may exhibit a variety of release profiles including profiles in which substantially all of the teprenone contained in the first component is released rapidly upon administration of the dosage form, released rapidly but after a time delay (delayed release), or released slowly over time.
  • the teprenone contained in the first component is released rapidly upon administration to a patient.
  • released rapidly includes release profiles in which at least about 80% of the active ingredient of a component is released within about an hour after administration
  • delayed release includes release profiles in which the active ingredient of a component is released (rapidly or slowly) after a time delay
  • controlled release and extended release include release profiles in which at least about 80% of the active ingredient contained in a component is released slowly.
  • the second teprenone component of such embodiment may also exhibit a variety of release profiles including an immediate release profile, a delayed release profile or a controlled release profile.
  • the second teprenone component exhibits a delayed release profile in which the teprenone of the component is released after a time delay.
  • the plasma profile produced by the administration of dosage forms of the present invention which comprise an immediate release teprenone component and at least one modified release teprenone component can be substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially, or to the plasma profile produced by the administration of separate IR and modified release dosage forms. Accordingly, the dosage forms of the present invention can be particularly useful for administering teprenone where the maintenance of pharmacokinetic parameters may be desired but is problematic.
  • the composition and the solid oral dosage forms containing the composition release the teprenone such that substantially all of the teprenone contained in the first component is released prior to release of the teprenone from the at least one second component.
  • the first component comprises an IR component
  • release of the teprenone from subsequent components may be delayed until substantially all of the teprenone contained in the first component has been released, and further delayed until at least a portion the teprenone released from the first component has been cleared from the patient's system.
  • release of the teprenone from subsequent components of the composition is substantially, if not completely, delayed for a period of at least about two hours after administration of the composition.
  • the release of teprenone from subsequent components of the composition is substantially, if not completely, delayed for a period of at least about four hours after administration of the composition.
  • the present invention also includes various types of modified release systems by which teprenone may be delivered in either a pulsatile or continuous manner.
  • modified release systems by which teprenone may be delivered in either a pulsatile or continuous manner.
  • These systems include but are not limited to: films with teprenone in a polymer matrix (monolithic devices); teprenone contained by the polymer (reservoir devices); polymeric colloidal particles or microencapsulates (microparticles, microspheres or nanoparticles) in the form of reservoir and matrix devices; teprenone contained by a polymer containing a hydrophilic and/or leachable additive e.g., a second polymer, surfactant or plasticizer, etc.
  • a hydrophilic and/or leachable additive e.g., a second polymer, surfactant or plasticizer, etc.
  • teprenone release may be osmotically controlled (both reservoir and matrix devices); enteric coatings (ionizable and dissolve at a suitable pH); (soluble) polymers with (covalently) attached pendant drug molecules; and devices where release rate is controlled dynamically: e.g., the osmotic pump.
  • the delivery mechanism of the present invention can control the rate of release of teprenone. While some mechanisms will release teprenone at a constant rate, others will vary as a function of time depending on factors such as changing concentration gradients or additive leaching leading to porosity, etc. Polymers used in sustained release coatings are necessarily biocompatible, and ideally biodegradable.
  • a typical approach to modified release is to encapsulate or contain the drug entirely (e.g., as a core), within a polymer film or coat (i.e., microcapsules or spray/pan coated cores).
  • reservoir devices e.g., the effects of additives, polymer functionality (and, hence, sink- solution pH) porosity, film casting conditions, etc.
  • modeling the release characteristics of reservoir devices (and monolithic devices) in which the transport of the drug is by a solution-diffusion mechanism therefore typically involves a solution to Fick's second law (unsteady-state conditions; concentration dependent flux) for the relevant boundary conditions.
  • the rate of release decreases exponentially with time as the concentration (activity) of the agent (i.e., the driving force for release) within the device decreases (i.e., first order release). If, however, the active agent is in a saturated suspension, then the driving force for release is kept constant until the device is no longer saturated.
  • the release-rate kinetics may be desorption controlled, and a function of the square root of time.
  • Transport properties of coated tablets may be enhanced compared to free- polymer films, due to the enclosed nature of the tablet core (permeant) which may enable the internal build-up of an osmotic pressure which will then act to force the permeant out of the tablet.
  • Coated salt tablets shaped as disks, were found to swell in de-ionized water and change shape to an oblate spheroid as a result of the build-up of internal hydrostatic pressure: the change in shape providing a means to measure the force generated.
  • the osmotic force decreased with increasing levels of PEG content.
  • the lower PEG levels allowed water to be imbibed through the hydrated polymer, while the porosity resulting from the coating dissolving at higher levels of PEG content (20 to 40%) allow the pressure to be relieved by the flow of KCl.
  • Monolithic (matrix) devices are commonly used for controlling the release of drugs. This is possibly because they are relatively easy to fabricate compared to reservoir devices, and the danger of an accidental high dosage that could result from the rupture of the membrane of a reservoir device is not present.
  • the active agent is present as a dispersion within the polymer matrix, and they are typically formed by the compression of a polymer/drug mixture or by dissolution or melting.
  • the dosage release properties of monolithic devices may be dependent upon the solubility of the drag in the polymer matrix or, in the case of porous matrixes, the solubility in the sink solution within the particle's pore network, and also the tortuosity of the network (to a greater extent than the permeability of the film), dependent on whether the drug is dispersed in the polymer or dissolved in the polymer.
  • the drug will be released by a solution-diffusion mechanism (in the absence of pores).
  • the release mechanism will be complicated by the presence of cavities formed near the surface of the device as the drug is lost: such cavities fill with fluid from the environment increasing the rate of release of the drug.
  • plasticizer e.g., a poly(ethylene glycol)
  • a surfactant i.e., an ingredient which increases effectiveness
  • adjuvant i.e., an ingredient which increases effectiveness
  • matrix devices and reservoir devices
  • plasticizers may be fugitive, and simply serve to aid film formation and, hence, decrease permeability - a property normally more desirable in polymer paint coatings.
  • leaching of PEG increased the permeability of (ethyl cellulose) films linearly as a function of PEG loading by increasing the porosity, however, the films retained their barrier properties, not permitting the transport of electrolyte.
  • surfactant may increase the drug release rate by three possible mechanisms: (i) increased solubilization, (ii) improved 'wettability' to the dissolution media, and (iii) pore formation as a result of surfactant leaching.
  • Composite devices consisting of a polymer/drug matrix coated in a polymer containing no drug also exist. Such a device was constructed from aqueous Eudragit ® lattices, and was found to provide a continuous release by diffusion of the drug from the core through the shell. Similarly, a polymer core containing the drug has been produced and coated with a shell that was eroded by gastric fluid. The rate of release of the drug was found to be relatively linear (a function of the rate limiting diffusion process through the shell) and inversely proportional to the shell thickness, whereas the release from the core alone was found to decrease with time.
  • Hollow microspheres were formed by preparing a solution of ethanol/dichloromethane containing the drug and polymer. On pouring into water, an emulsion is formed containing the dispersed polymer/drug/solvent particles, by a coacervation-type process from which the ethanol rapidly diffused precipitating polymer at the surface of the droplet to give a hard-shelled particle enclosing the drug dissolved in the dichloromethane. A gas phase of dichloromethane was then generated within the particle which, after diffusing through the shell, was observed to bubble to the surface of the aqueous phase.
  • the hollow sphere at reduced pressure, then filled with water which could be removed by a period of drying. No drug was found in the water.
  • Highly porous matrix-type microspheres have also been described.
  • the matrix-type microspheres were prepared by dissolving the drug and polymer in ethanol. On addition to water, the ethanol diffused from the emulsion droplets to leave a highly porous particle.
  • a suggested use of the microspheres was as floating drug delivery devices for use in the stomach.
  • Pendent devices A means of attaching a range of drugs such as analgesics and antidepressants, etc., by means of an ester linkage to poly(acrylate) ester latex particles prepared by aqueous emulsion polymerization has been developed. These lattices, when passed through an ion exchange resin such that the polymer end groups were converted to their strong acid form, could self-catalyze the release of the drug by hydrolysis of the ester link.
  • Drugs have been attached to polymers, and also monomers have been synthesized with a pendent drug attached. Dosage forms have been prepared in which the drug is bound to a biocompatible polymer by a labile chemical bond e.g., polyanhydrides prepared from a substituted anhydride (itself prepared by reacting an acid chloride with the drug: methacryloyl chloride and the sodium salt of methoxy benzoic acid) were used to form a matrix with a second polymer (Eudragit ® RL) which released the drug on hydrolysis in gastric fluid.
  • polyanhydrides prepared from a substituted anhydride (itself prepared by reacting an acid chloride with the drug: methacryloyl chloride and the sodium salt of methoxy benzoic acid) were used to form a matrix with a second polymer (Eudragit ® RL) which released the drug on hydrolysis in gastric fluid.
  • Enteric films consist of pH sensitive polymers. Typically the polymers are carboxylated and interact very little with water at low pH, while at high pH the polymers ionize causing swelling or dissolving of the polymer. Coatings can therefore be designed to remain intact in the acidic environment of the stomach, protecting either the drug from this environment or the stomach from the drug, but to dissolve in the more alkaline environment of the intestine.
  • the osmotic pump is similar to a reservoir device but contains an osmotic agent (e.g., the active agent in salt form) which acts to imbibe water from the surrounding medium via a semi-permeable membrane.
  • an osmotic agent e.g., the active agent in salt form
  • Such a device called an elementary osmotic pump, has been described.
  • Pressure is generated within the device which forces the active agent out of the device via an orifice of a size designed to minimize solute diffusion, while preventing the build-up of a hydrostatic pressure head which can have the effect of decreasing the osmotic pressure and changing the dimensions of the device.
  • the internal volume of the device remains constant, and there is an excess of solid or saturated solution in the device, then the release rate remains constant delivering a volume equal to the volume of solvent uptake.
  • Monolithic devices have been prepared using polyelectrolyte gels which swell when, for example, an external electrical stimulus is applied causing a change in pH.
  • the release may be modulated by changes in the applied current to produce a constant or pulsatile release profile.
  • hydrogels find use in a number of biomedical applications such as, for example, soft contact lenses, and various soft implants, and the like.
  • a method for treating a patient suffering from pain and/or inflammation comprising the step of administering a therapeutically effective amount of the teprenone composition of the present invention in solid oral dosage form.
  • Advantages of the method of the present invention include a reduction in the dosing frequency required by conventional multiple IR dosage regimes while still maintaining the benefits derived from a pulsatile plasma profile or eliminating or minimizing the variations in plasma concentration levels. This reduced dosing frequency is advantageous in terms of patient compliance and the reduction in dosage frequency made possible by the method of the present invention would contribute to controlling health care costs by reducing the amount of time spent by health care workers on the administration of drugs.
  • purified water refers to water that has been purified by passing it through a water filtration system. It is to be understood that the examples are for illustrative purposes only, and should not be interpreted as restricting the spirit and breadth of the invention as defined by the scope of the claims that follow.
  • a multiparticulate modified release composition according to the present invention comprising an immediate release component and a modified release component containing teprenone is prepared as follows.
  • a solution of teprenone (50:50 racemic mixture) is prepared according to any of the formulations given in Table 1.
  • the methylphenidate solution is then coated onto nonpareil seeds to a level of approximately 16.9% solids weight gain using, for example, a Glatt GPCG3 (Glatt, Protech Ltd., Leicester, UK) fluid bed coating apparatus to form the IR particles of the immediate release component.
  • Glatt GPCG3 Glatt, Protech Ltd., Leicester, UK
  • Teprenone-containing delayed release particles are prepared by coating immediate release particles prepared according to Example l(a) above with a modified release coating solution as detailed in Table 2.
  • the immediate release particles are coated to varying levels up to approximately to 30% weight gain using, for example, a fluid bed apparatus.
  • Talc 1 16.0 5.9 16.3 2.8 2.25 i Talc is simultaneously applied during coating for formulations in column (i), (iv) and (vi). (c) Encapsulation of Immediate and Delayed Release Particles.
  • the immediate and delayed release particles prepared according to Example l(a) and (b) above are encapsulated in size 2 hard gelatin capsules to an overall 20 mg dosage strength using, for example, a Bosch GKF 4000S encapsulation apparatus.
  • the overall dosage strength of 20 mg teprenone was made up of 10 mg from the immediate release component and 10 mg from the modified release component.
  • Multiparticulate modified release teprenone compositions according to the present invention having an immediate release component and a modified release component having a modified release matrix material are prepared according to the formulations shown in Table 5(a) and (b). TABLE 5 (a)
  • IR component 100 mg is encapsulated with 100 mg of modified release (MR) component to give a 20 mg dosage strength product
  • IR component 50 mg is encapsulated with 50 mg of modified release (MR) component to give a 20 mg dosage strength product.
  • MR modified release

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions qui comprennent une nanoparticule de téprénone à biodisponibilité améliorée. Les nanoparticules de téprénone de la composition ont une taille moyenne efficace de particule inférieure à environ 2000 nm et sont utiles dans la prévention et le traitement de gastrites et d’ulcères gastriques. L'invention concerne également une composition à libération contrôlée qui comprend une téprénone ou une nanoparticule de téprénone qui délivre lors de l'utilisation le médicament d’une manière pulsée ou multimodale utilisée pour la prévention et le traitement de gastrites et d’ulcères gastriques.
PCT/US2006/018000 2005-05-10 2006-05-09 Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone WO2007070082A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67942405P 2005-05-10 2005-05-10
US60/679,424 2005-05-10
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
US11/372,857 2006-03-10

Publications (1)

Publication Number Publication Date
WO2007070082A1 true WO2007070082A1 (fr) 2007-06-21

Family

ID=38163239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018000 WO2007070082A1 (fr) 2005-05-10 2006-05-09 Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone

Country Status (1)

Country Link
WO (1) WO2007070082A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002568A2 (fr) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Formulations d'agent actif, procédé d'élaboration et d'utilisation
WO2013053793A1 (fr) * 2011-10-14 2013-04-18 Dsm Ip Assets B.V. Nouveau système d'enrobage
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814353A (en) * 1985-07-04 1989-03-21 Eisai Co., Ltd. Therapeutic and prophylactic agent for gastritis
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814353A (en) * 1985-07-04 1989-03-21 Eisai Co., Ltd. Therapeutic and prophylactic agent for gastritis
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002568A2 (fr) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Formulations d'agent actif, procédé d'élaboration et d'utilisation
WO2008002568A3 (fr) * 2006-06-26 2008-04-17 Mutual Pharmaceutical Co Formulations d'agent actif, procédé d'élaboration et d'utilisation
WO2013053793A1 (fr) * 2011-10-14 2013-04-18 Dsm Ip Assets B.V. Nouveau système d'enrobage
US9609885B2 (en) 2011-10-14 2017-04-04 Dsm Ip Assets B.V. Coating system
US10449159B2 (en) 2014-10-31 2019-10-22 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10111839B2 (en) 2014-10-31 2018-10-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10292939B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10292938B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10500162B2 (en) 2014-10-31 2019-12-10 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10507186B2 (en) 2014-10-31 2019-12-17 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10512612B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10512613B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10568841B2 (en) 2014-10-31 2020-02-25 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10688060B2 (en) 2014-10-31 2020-06-23 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11896722B2 (en) 2014-10-31 2024-02-13 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Similar Documents

Publication Publication Date Title
US8119163B2 (en) Nanoparticulate and controlled release compositions comprising cefditoren
AU2007260822B2 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20080113025A1 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20080102121A1 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
AU2007260821B2 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070160675A1 (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
US20110064800A1 (en) Nanoparticulate and controlled release compositions comprising cyclosporine
US20090269400A1 (en) Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
US20090297596A1 (en) Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
WO2008008879A2 (fr) Formulations de nanoparticules de modafinil
US20110064803A1 (en) Nanoparticulate and controlled release compositions comprising vitamin k2
WO2007027273A1 (fr) Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
US20090252807A1 (en) Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
WO2007070082A1 (fr) Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone
WO2008073068A1 (fr) Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren
US20100247636A1 (en) Nanoparticulate and controlled release compositions comprising nilvadipine
WO2007106111A2 (fr) Compositions nanoparticulaires et a liberation controlee comprenant de la nilvadipine
AU2006343445B8 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06759450

Country of ref document: EP

Kind code of ref document: A1